Ten stocks kicked off Monday’s trading leading the charge, in line with the overall market optimism, as investors cheered the looming end of a government shutdown, while taking cues from more corporate earnings and upbeat outlooks. Of the 10 in the list, five surged to new record highs, with one notably soaring by more tha 100 percent.
Meanwhile, Wall Street’s major indices all finished in the green, led by the tech-heavy Nasdaq, up 2.27 percent, followed by the S&P 500, jumping 1.54 percent, and the Dow Jones, rising 0.81 percent.
This article focuses on the 10 big names that outperformed, alongside the reasons behind their gains.
To come up with the list, we considered only the stocks with a $2 billion market capitalization and more than 5 million shares in trading volume.
A man in black suit holding a tablet looks at stock market data on a monitor. Photo by Tima Miroshnichenko on Pexels
10. 10x Genomics Inc. (NASDAQ:TXG)
Shares of 10x Genomics propelled to a new 52-week high after narrowing its net loss and beating its revenue guidance for the third quarter of the year.
At intra-day trading, the stock jumped to its highest price of $17.28 before paring gains to end the day just up by 12 percent at $17.08 apiece.
In an updated report, 10x Genomics Inc. (NASDAQ:TXG) said it narrowed its net loss in the third quarter by 23 percent to $27.47 million from $35.75 million in the same period last year.
Revenues, on the other hand, declined by 1.7 percent to $149 million from $151.6 million in the same comparable period, primarily due to a decrease in instrument revenue. However, the figure beat the company’s earlier guidance of $140 million to $144 million.
Looking ahead, 10x Genomics Inc. (NASDAQ:TXG) expects the fourth quarter of the year to be in the range of $154 million to $158 million, or an expected decline of 6 percent year-on-year, but a growth of 5 percent at the midpoint on a quarter-on-quarter basis.
“This outlook reflects the continuation of the key positive drivers of performance that we’ve seen throughout this year. We do not anticipate a material change in customer purchasing behavior and do not anticipate the year-end budget acceleration we have previously experienced in the fourth quarter,” said 10x Genomics Inc. (NASDAQ:TXG) CEO Serge Saxonov.
9. Pagaya Technologies Ltd. (NASDAQ:PGY)
Pagaya Technologies rallied for a second day on Monday, jumping 12.80 percent to close at $27.58 after beating its earnings expectations in the past quarter and raising its growth guidance for the full-year 2025.
In an updated report, Pagaya Technologies Ltd. (NASDAQ:PGY) said it swung to a net income attributable to shareholders of $22.5 million from $67.48 million in the same period last year, beating its earlier guidance of $10 million to $20 million for the period, thanks to revenue growth, lower expenses, and normalized impairments.
Total revenues and other income ended at $350 million, hitting the higher end of its previous revenue guidance and marking a 36 percent growth from the $257 million year-on-year, driven by higher revenues from fees.
Following the results, Pagaya Technologies Ltd. (NASDAQ:PGY) raised its full-year guidance for net profit, revenues, and adjusted EBITDA, among others.
Net income is now targeted at a range of $72 million to $82 million, versus $55 million to $75 million previously.
Revenues are also expected to increase to a range of $1.3 billion to $1.325 billion, from its previous expectations of at least $1.25 billion.
For the fourth quarter alone, net income is projected to settle anywhere between $25 million and $35 million, while revenues are expected to be at $333 million to $358 million.
8. SolarEdge Technologies Inc. (NASDAQ:SEDG)
SolarEdge propelled to a new 52-week high on Monday after rallying for two days in a row, as investors cheered the results of its earnings performance in the third quarter of the year and partnership announcements to support AI data centers.
At intra-day trading, the stock jumped to its highest price of $48.60 before trimming gains to end the day just up by 13.45 percent at $45.38 apiece.
In an updated report, SolarEdge Technologies Inc. (NASDAQ:SEDG) said it trimmed its net loss in the third quarter of the year by 96 percent to $50.06 million from $1.23 billion in the same period last year, on the back of higher gross profit and lower operating loss.
Revenues jumped by 44.68 percent to $340 million from $235 million year-on-year, falling within its earlier guidance of $315 million to $355 million.
In other news, SolarEdge Technologies Inc. (NASDAQ:SEDG) announced that it joined forces with Infineon Technologies for the design and development of a Solid-State Transformer (SST) platform capable of powering the next-generation AI and hyperscale data centers.
SolarEdge Technologies Inc. (NASDAQ:SEDG) said that the new technology would be designed to support 800-volt direct current (VDC) AI data center power architectures.
7. Organon & Co. (NYSE:OGN)
Organon extended its winning streak to a third straight day on Monday, jumping 13.72 percent to close at $7.71 as investors snapped up shares ahead of the record date for its next quarterly dividend payment, despite weak earnings results for the third quarter.
In an updated report, Organon & Co. (NYSE:OGN) said it would distribute $0.02 worth of dividends to all common shareholders as of November 20, 2025, payable on December 11, 2025.
This followed the results of its earnings performance in the third quarter of the year, where it registered $160 million in net income, lower by 55 percent than the $359 million in the same period last year.
Revenues, on the other hand, inched up by 1 percent to $1.6 billion from $1.58 billion year-on-year, on the back of higher revenues from general medicines, which offset the drop in revenues from women’s health.
Following the results, Organon & Co. (NYSE:OGN) lowered its revenue guidance for full-year 2025 to a range of $6.2 billion to $6.25 billion from $6.275 billion to $6.375 billion previously.
Expectations for adjusted EBITDA margin were also reduced to 31 percent from up to 32 percent earlier.
Organon & Co. (NYSE:OGN) is a US-based global pharmaceutical company specializing in women’s health, biosimilars, and reproductive health, among others.
6. Canadian Solar Inc. (NASDAQ:CSIQ)
Canadian Solar soared to a new two-year high on Monday, as investors loaded portfolios ahead of the results of its earnings performance in the third quarter of the year.
At intra-day trading, Canadian Solar Inc. (NASDAQ:CSIQ) surged to its highest price of $33.30 before paring gains to end the day just up by 13.80 percent at $32.40 apiece.
In a notice to investors, Canadian Solar Inc. (NASDAQ:CSIQ) said it would release the results of its third quarter earnings performance before market open on Thursday, November 13. A conference call will be held to elaborate on the results.
In recent news, Canadian Solar Inc.’s (NASDAQ:CSIQ) subsidiary—e-STORAGE—successfully commissioned a new 220 MWh battery storage system owned by Epic Energy in Australia.
e-STORAGE was tapped as the Engineering, Procurement, and Construction (EPC) provider for the project.
Under a long-term service agreement, e-STORAGE will support the project’s ongoing performance and operational management, demonstrating its commitment to long-term value creation.
“We are delighted to support Epic Energy in reinforcing South Australia’s grid resilience and accelerating the shift towards clean energy…With over 1.8 GWh of BESS under construction in Australia, e-STORAGE continues to establish itself as a leading product and solution provider in the region,” said e-STORAGE President Colin Parkin.
Through e-STORAGE, Canadian Solar Inc. (NASDAQ:CSIQ) has shipped over 13 GWh of battery energy storage solutions to global markets, boasting a $3 billion contracted backlog as of June 30, 2025.
5. XPeng Inc. (NYSE:XPEV)
XPeng saw its share prices jump by 16.15 percent on Monday to finish at $26.04 apiece as investors loaded portfolios ahead of the release of an expected stellar earnings performance in the third quarter of the year.
In a notice posted on its website, XPeng Inc. (NYSE:XPEV) said it would announce its financial and operating highlights for the third quarter before market open on Monday, November 17.
XPeng Inc. (NYSE:XPEV) earlier provided guidance for the third quarter period, with total revenues expected to grow by 94 to 108 percent year-on-year to a range of 19.6 billion to 21 billion yuan.
Additionally, XPeng Inc. (NYSE:XPEV) successfully hit 116,007 vehicle deliveries during the period, marking a 149 percent jump year-on-year. The total number also fell within the company’s expectations of 113,000 to 118,000 vehicle deliveries for the period.
In other news, XPeng Inc. (NYSE:XPEV) officially filed an application with the Ministry of Industry and Information Technology for the launch of the extended range version of its G6 SUV—the G6 EREV, in line with its plans to ramp up its electric vehicle offerings, although the official launch date has yet to be divulged.
4. Tower Semiconductor Ltd. (NASDAQ:TSEM)
Tower Semiconductor bounced back from two straight days of losses on Monday to hit a new 11-year high after beating its revenue guidance for the third quarter of the year and raising its growth outlook for the fourth quarter.
At intra-day trading, Tower Semiconductor Ltd. (NASDAQ:TSEM) soared to its highest price of $99.82 before paring gains to end the day just up by 16.69 percent at $98.10 apiece.
In an updated report, the company said it incurred $396 million in revenues in the third quarter of the year, higher by 6.8 percent than the $370.5 million in the same period last year and beating the company’s earlier guidance of $395 million.
Net profit, however, dipped by 2.5 percent to $53.4 million from $54.8 million year-on-year amid higher costs and expenses.
For the fourth quarter, Tower Semiconductor Ltd. (NASDAQ:TSEM) expects revenues to increase by 14 percent year-on-year to $440 million, with an upward or downward range of 5 percent.
“We are in the best position, our core technologies—Power Management, Image Sensors and 65nm RF Mobile—each demonstrating year over year revenue growth. This is an excellent foundation, on top of which our number one position in SiGe and SiPho technologies for optical transceivers, combined with data center surging demand, gives Tower a present and future pathway for unprecedented growth—both top and bottom line, given the accretive margins of these value-add solutions,” said Tower Semiconductor Ltd. (NASDAQ:TSEM) CEO Russell Ellwanger.
3. Opendoor Technologies Inc. (NASDAQ:OPEN)
Opendoor grew its share prices by 21.49 percent on Monday to close at $7.97 apiece after beating its revenue guidance for the third quarter and updating its financial outlook for the fourth quarter.
In an updated report, Opendoor Technologies Inc. (NASDAQ:OPEN) said it incurred revenues of $915 million in the third quarter of the year, a decline of 33 percent from the $1.377 billion in the same period last year, but exceeded its earlier guidance of $800 million to $875 million.
Net loss, on the other hand, widened by 15 percent to $90 million from $78 million in the same comparable period, amid a 37 percent lower gross profit.
Opendoor Technologies Inc. (NASDAQ:OPEN) updated its financial outlook, with adjusted net income expected to break even by the end of next year.
For the fourth quarter of 2025, Opendoor Technologies Inc. (NASDAQ:OPEN) expects revenues to decrease by 35 percent sequentially due to low inventory levels from reduced acquisition volumes in the third quarter, but acquisition activities are expected to pick up during the current period.
It also targets to book adjusted EBITDA loss of high $40 millions to mid $50 millions in the fourth quarter of the year.
2. Navitas Semiconductor Corp. (NASDAQ:NVTS)
Navitas snapped a five-day losing streak on Monday, soaring 22.45 percent to close at $9.60 apiece, after successfully raising $100 million in fresh funds to finance its expansion program.
In an updated report, Navitas Semiconductor Corp. (NASDAQ:NVTS) said it sold more than 14.8 million new common shares under a private placement at a price of $6.75 apiece.
“This capital raise enables us to support Navitas’ transformation and accelerate our momentum into higher-power markets,” said Navitas Semiconductor Corp. (NASDAQ:NVTS) President and CEO Chris Allexandre.
“We’re fueling and energizing the shift to Navitas 2.0, focusing our energy on the high-power markets that are shaping the future: AI data centers, performance computing, energy and grid infrastructure, and industrial electrification,” he added.
The share sale followed the results of the company’s earnings performance in the third quarter of the year.
During the period, Navitas Semiconductor Corp. (NASDAQ:NVTS) incurred a 2.7 percent higher net loss of $19.2 million, versus the $18.7 million year-on-year.
Revenues also dropped by 53.4 percent to $10.1 million from $21.68 million in the same comparable period.
For the fourth quarter of the year, Navitas Semiconductor Corp. (NASDAQ:NVTS) expects revenues to be at $7 million, plus or minus $250,000, due to a strategic decision to deprioritize low power, lower profit from China mobile and consumer business, as well as streamline distribution network and reduce channel inventory to pivot to higher power revenue and customers.
1. Cogent Biosciences, Inc. (NASDAQ:COGT)
Cogent Biosciences soared to a new seven-year high on Monday, as investors cheered promising results of the last clinical trial phase that tested the efficacy of its drug candidate for a type of stomach cancer called Gastrointestinal Stromal Tumors (GIST).
At intra-day trading, the stock climbed to its highest price of $36.15 before paring gains to end the day just up by 119.03 percent at $32.46 apiece.
In an updated report, Cogent Biosciences, Inc. (NASDAQ:COGT) said it is set to file a new drug application with the Food and Drug Administration for its treatment candidate, bezuclastinib, in combination with sunitinib, after its phase 3 trial showed promising developments.
During the study, patients with Gastrointestinal Stromal Tumors (GIST) who took bezuclastinib in combination with sunitinib saw an average of 16.5 months without their cancer worsening, as compared with the 9.2 months for those who took sunitinib alone.
In addition, 46 percent of the patients who took the combo saw their tumors shrink, versus the 26 percent of patients who took sunitinib alone.
Cogent Biosciences, Inc. (NASDAQ:COGT) President and CEO Andrew Robbins said that the results surpassed the company’s expectations.
“With these incredible results, including a greater than seven-month improvement on mPFS (median progression-free survival)—reducing the rate of progression or death by half—the bezuclastinib combination is poised to become the new standard of care for treatment of second-line GIST patients,” he said.
Following the results, Cogent Biosciences, Inc. (NASDAQ:COGT) announced plans to raise $200 million through the issuance of convertible senior notes due 2031.
The notes will be general, unsecured, and will mature on November 15, 2031, unless earlier converted to cash or stocks, redeemed, or repurchased.
Proceeds will be used to repay $50 million outstanding loans, with the remainder to be used to fund the development and regulatory activities for the expected launch and commercialization of bezuclastinib, alongside other drug candidates.
While we acknowledge the potential of COGT to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than COGT and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge fund investor letters by entering your email below.
